Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2007-09-18
2007-09-18
Wehbé, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093210, C435S366000, C435S372000, C435S325000
Reexamination Certificate
active
10169028
ABSTRACT:
A method of transplanting a transplant derived from a donor into a recipient is disclosed. The method comprises the steps of (a) transplanting the transplant into the recipient; and (b) administering to the recipient a dose including non-alloreactive anti-third party cytotoxic T-lymphocytes (CTLs), wherein the non-alloreactive anti-third party CTLs are generated by directing T-lymphocytes of the donor against a third party antigen or antigens, the dose is substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, thereby preventing or ameliorating both graft rejection by the recipient and graft versus host disease.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4801531 (1989-01-01), Frossard
patent: 4879219 (1989-11-01), Wands et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5192659 (1993-03-01), Simons
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5281521 (1994-01-01), Trojanowski et al.
patent: 6544506 (2003-04-01), Reisner
Kaufman et al. (1995) Annu. Rev. Immunol., vol. 13, 339-367.
Jacobsen and Claesson (1998) APMIS, vol. 106, 345-353.
Cavazzano-Calvo et al. (1994) Blood, vol. 83(1), 288-298.
Reisner et al. (1998) Blood, vol. 92(10), 265a.
Bachar-Lustig et al “Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1(+)Lin(−) bone marrow progenitor cells: synergism with non-alloreactive (host x donor)F(1) T cells”,Blood. Nov. 1, 1999;94(9):3212-21.
Miller, RG, “An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it”,Nature. Oct. 9, 1980;287(5782):544-6.
Kaufman et al, “Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells”,Blood. Oct. 15, 1994;84(8):2436-46.
Pierce et al, “Do donor cells function as veto cells in the induction and maintenance of tolerance across an MHC disparity in mixed lymphoid radiation chimeras?”Transplantation. Apr. 1993;55(4):882-7.
Cobbold et al “Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance”,Nature. Sep. 11-17, 1986;323(6084):164-6.
Goodwin et al, “Isolation of cell lines possessing functional and serological properties resembling those of thymocyte precursors”,Nature. Sep. 1-17, 1986; 323(6084):166-9.
Sugiura et al, “Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity”,Proc Natl Acad Sci U S A. Jul. 1988;85(13):4824-6.
Hiruma et al., “Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes,”J Exp Med. Mar. 1, 1992;175(3):863-8.
Pierce et al, “Thy 1+ donor cells function as veto cells in the maintenance of tolerance across a major histocompatibility complex disparity in mixed-lymphoid radiation chimeras”,Transplant Proc. Feb. 1993;25(1 Pt 1):331-3.
Strober et al, “Cloned natural suppressor cells prevent lethal graft-vs-host disease”,J Immunol. Feb. 1, 1987;138(3):699-703.
Tscherning et al “Veto-like down-regulation of T helper cell reactivity in vivo by injection of semi-allogeneic spleen cells”,Immunol Lett. Aug. 1991;29(3):223-7.
Cassell et al, “Regulation of the cytotoxic T lymphocyte response against Qa-1 alloantigens”,J Immunol. Jun. 1, 1990;144(11):4075-81.
Claesson et al “Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures”,Curr Top Microbiol Immunol. 1986;126:213-23.
Fink et al, “Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them”J Immunol. Oct. 1984;133(4):1775-81.
Tscherning et al, “Veto suppression: the peripheral way of T cell tolerization”,Exp Clin Immunogenet. 1993;10(4):179-88.
Claaesson, MH, “Veto cell H-2 antigens: veto cell activity is restricted by determinants encoded by K, D, and I MHC regions”,Cell Immunol. Oct. 15, 1987;109(2):360-70.
Sambhara et al, “Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC”,Science. Jun. 7, 1991;252(5011):1424-7.
Sambhara et al, “Reduction of CTL antipeptide response mediated by CD8+ cells whose class I MHC can bind the peptide”,J Immunol. Feb. 1, 1994;152(3):1103-9.
Hiruma et al, “Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes”,J Exp Med. Mar. 1, 1992;175(3):863-8.
Qi et al, Hybrid antibody mediated veto of cytotoxic T lymphocyte responses.J Exp Med. May 1, 1996;183(5):1973-80.
Asiedu et al, “Immunoregulatory role of CD8alpha in the veto effect”,Transplantation. Feb. 15, 1999;67(3):372-80.
George et al, “The molecular mechanisms of veto mediated regulation of alloresponsiveness”,J Mol Med. Jul. 1999;77(7):519-26.
Reisner et al, “Non Alloreactive Donor Anti-Third Party CTLs Facilitate BM Allografts Across Major Histocompatibility Barriers in Sublethally Irradiated Mice”,Blood, 92:265a, 1998.
Reich-Zeliger et al, “Enhancement of BM Allografts by Non-Alloreactive Donor CTL's: CD8 Binding and Fas-FasL Apoptosis Mediate the Veto Effect”,Blood, 94(10) S. 1, 1999.
Aversa et al, “Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype”,N Engl J Med. Oct. 22, 1998;339(17):1186-93.
Hillyer et al, “Peripheral blood stem cell acquisition by large-volume leukapheresis in growth factor-stimulated and unstimulated rhesus monkeys: development of an animal model”,Exp Hematol. Oct. 1993;21(11):1455-9.
Bachar-Lustig et al, “Murine and Human Non-Alloreactive Anti-3rdParty CTL: A Novel Facilitating Cell With Markedly Reduced GVH Reactivity”,Blood, 96(111):3739 (Abstract No. 1610), 2000.
Reich-Zeliger et al, “Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite”,Immunity. Oct. 2000;13(4):507-15.
Gilboa et al, “Transfer And Expression Of Cloned Genes Using Retroviral Vectors”,BioTechniques, 4(6):504-512, 1986.
Fink et al, “Veto Cells”,Ann Rev Immunol, 6:115:-137, 1988.
Lapidot et al, “Enhancement of T-cell-depleted bone marrow allografts in the absence of graft-versus-host disease is mediated by CD8+ CD4− and not by CD8− CD4+ thymocytes”,Blood. Nov. 1, 1992;80(9):2406-11.
Martelli Massimo
Reisner Yair
Wehbe Anne M.
Yeda Research and Development Co. Ltd.
LandOfFree
Veto cells effective in preventing graft rejection and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Veto cells effective in preventing graft rejection and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Veto cells effective in preventing graft rejection and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793273